References

References

  1. Pierce, B. G., Boucher, E. N., Piepenbrink, K. H., Ejemel, M., Rapp. C. A., Thomas, W. D., Jr., Sundberg, E. J., Weng, Z., Wang, Y., 2017. Structure based design of hepatitis C virus vaccines that elicit neutralizing antibody responses to a conserved epitope. J Virol 91:1032-17.
  2. Broering, T. J., Garrity, K. A., Boatright, N. K., Sloan, S. E., Sandor, F., Thomas, W. D., Jr., Szabo, G., Finberg, R. W., Ambrosino, D. M., Babcock, G. J. 2009. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83:12473–12482.
  3. Chung, R. T., Gordon, F. D., Curry, M. P., Schiano, T. D., Emre, S., Corey, K., Markmann, J. F., Hertl, M., Pomposelli, J. J., Pomfret, E. A., Florman, S., Schilsky, M., Broering, T. J., Finberg, R. W., Szabo, G., Zamore, P. D., Khettry, U., Babcock, G. J., Ambrosino, D. M., Leav, B., Leney, M., Smith, H. L., Molrine, D. C. 2013. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant 13:1047–1054.
  4. Kong, L., Jackson, K. N., Wilson, I. A., Law, M., 2015. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 11:148 –157.
  5. He, L., Cheng, Y., Kong, L., Azadnia, P., Giang, E., Kim, J., Wood, M. R., Wilson, I. A., Law, M., Zhu, J., 2015. Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep 5:12501.
  6. Sandomenico, A., Leonardi, A., Berisio, R., Sanguigno, L., Foca, G., Foca, A., Ruggiero, A., Doti, N., Muscariello, L., Barone, D., Farina, C., Owsianka, A., Vitagliano, L., Patel, A. H., Ruvo, M., 2016. Generation and characterization of monoclonal antibodies against a cyclic variant of hepatitis C virus E2 epitope 412-422. J Virol 90:3745–3759.
  7. Halliday, J., Klenerman, P., Barnes, E., 2011. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10:659–672.
  8. Pantua, H., Diao, J., Ultsch, M., Hazen, M., Mathieu, M., McCutcheon, K., Takeda, K., Date, S., Cheung, T. K., Phung, Q., Hass, P., Arnott, D., Hongo, J. A., Matthews, D. J., Brown, A., Patel, A. H., Kelley, R. F., Eigenbrot, C., Kapadia, S. B., 2013. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 425:1899 –1914.
  9. Protein identification and analysis tools on the ExPASy server. Gasteiger, E. et. al. In J. M. Walker (Ed.) The proteomics protocols handbook. Totowa, New Jersey: Humana Press Inc. 2005.
  10. Molsoft L.L.C.: ICM-Browser. https://www.molsoft.com/icm_browser.html.
  11. Protein Data Bank. https://www.rcsb.org/structure/5KZP.
  12. Kong, L., Giang, E., Robbins, J. B., Stanfield, R. L., Burton, D. R., Wilson, I. A., Law, M. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109:9499 –9504.
  13. Basic Local Alignment Search Tool. National Center for Biotechnology Information. 2012. http://www.ncbi.nlm.nih.gov/blast/Blast.cgi
  14. Dali server: conservation mapping in 3D. Nucl. Acids Res. 38, W545-549. Holm L, Rosenström, P. 2010.
  15. Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, Ryu SE, Son JY, Lee JU, Heo YS. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. 2016. Nat Commun. 7:13354.
  16. Vietheer, P. T., Boo, I., Gu, J., McCaffrey, K., Edwards, S., Owczarek, C., Hardy, M. P., Fabri, L., Center, R. J., Poumbourios, P., Drummer, H. E., 2017. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology 65:1117–1131.